Pediococcus pentosaceus

Pediococcus pentosaceus

1. Identity, Classification, and General Characteristics

Pediococcus pentosaceus is a species of lactic acid bacteria (LAB) belonging to the genus Pediococcus within the family Lactobacillaceae. It is a species of cocci-shaped LAB that occurs in pairs or quadruplets and is a non-motile, facultative anaerobic, Gram-positive bacterium. It exhibits a spherical morphology and possesses a robust homofermentative metabolism, rendering it well-suited for thriving in anaerobic conditions. It is categorized as a lactic acid bacterium because the end product of its metabolism is lactic acid.

P. pentosaceus is a mesophile with optimal growth at 28–35 °C and cannot grow at 50 °C; yet it can tolerate salt concentrations of up to 10%, which is an important characteristic for its application in the preparation of pickled fermented food products. Most strains can ferment glucose, ribose, galactose, arabinose, and fructose to DL-lactate.

From a genomic standpoint, the P. pentosaceus chromosome is circular, measuring 1,734,928 bp with a GC content of 37.2%. Many strains also harbor a circular plasmid with a GC content of approximately 38.1%. The species is not host-specific and shares core genes encoding proteins related to translation, ribosomal structure and biogenesis, and signal transduction mechanisms, while its genetic diversity relates mainly to carbohydrate metabolism, and horizontally transferred DNA, especially prophages and bacteriocins encoded on plasmids.

P. pentosaceus has a long history of use and holds Generally Recognized As Safe (GRAS) status granted by the United States Food and Drug Administration (FDA), supporting its widespread use across the food fermentation industry. In the European Union, the species P. pentosaceus is considered by EFSA to be suitable for the Qualified Presumption of Safety (QPS) approach to safety assessment, and does not require specific demonstration of safety other than the absence of resistance to antibiotics of human and veterinary significance.

Common Names and Synonyms

Pediococcus pentosaceus has no widely used common name outside of its scientific designation. It is frequently referred to in the literature as PP, P. pentosaceus, or by its individual strain designations (e.g., LP28, LI05, KFT18, CECT 8330, ENM104). The bacterium has been studied since it was first described in the 1960s.

2. Natural Sources and Ecological Distribution

Its prevalence in a wide array of environments, including fermented foods, aquatic animal products, raw materials, plants, and feces, underscores its ecological significance and adaptive capabilities. Numerous studies have reported that strains of P. pentosaceus are frequently isolated from various food sources and biotopes encompassing plant materials, bacterial-ripened cheese, beverages, pickles, wine, dairy, and meat products, with a potent role as starter cultures involved in the manufacturing of fermented foods.

The species has been reported to be naturally associated with plants, fruits, plant fermentations, and meat materials. A few isolates have been detected in the gastrointestinal tracts of poultry and ducks as well as in freshwater prawns. Most strains available in public databases have been isolated from fermented food and the natural environment; only a limited number of P. pentosaceus strains isolated from the human gastrointestinal tract or fecal samples have been released and made available for analysis.

Representative foods and fermented products from which P. pentosaceus has been isolated include:

• Kimchi (Korea): P. pentosaceus strain wikim 20 is a lactic acid bacterium isolated from kimchi, a traditional Korean fermented food made from a variety of vegetables such as cabbage or radish with seasoning ingredients including red pepper powder, garlic, leek, ginger, and salt.
• Sauerkraut: Pediococcus pentosaceus is among the documented bacterial species present in sauerkraut fermentation.
• Laban (Middle East): a traditional fermented milk product from which P. pentosaceus has been isolated and assessed for probiotic potential.
• Fermented sausages (Italy): among LAB isolates from fermented sausages at different stages of ripening, 22% were identified as Pediococcus pentosaceus.
• Longan fruit: strain LP28 was newly isolated from this tropical fruit.
• Thai fermented foods: there are reports of isolation of Pediococcus pentosaceus from traditional Thai fermented foods containing fish and pork.
• Suancai (Chinese pickled vegetable): during fermentation, P. pentosaceus greatly increased the concentration of nitriles and alcohols in this traditional product.
• Jangajji: a traditional Korean fermented pickle from which P. pentosaceus strains have been isolated.

3. Traditional and Historical Use

Pediococcus pentosaceus, as a microorganism, has no separate history of intentional use under its scientific name in traditional medicine systems. Its history is one of inadvertent use as a component of traditional fermented foods — a practice that long preceded the identification of the organism itself. Fermented foods and beverages were among the first processed food products consumed by humans. The production of foods such as yogurt and cultured milk, wine and beer, sauerkraut and kimchi, and fermented sausage were initially valued because of their improved shelf life, safety, and organoleptic properties. It is increasingly understood that fermented foods can also have enhanced nutritional and functional properties due to transformation of substrates and formation of bioactive or bioavailable end-products.

P. pentosaceus, along with P. acidilactici, has long been a member of indigenous microflora and is often used as a starter culture in natural and controlled fermentations. This means that across East Asian, Middle Eastern, and European food traditions — in products ranging from Korean kimchi and sauerkraut to Lebanese laban and Italian dry-fermented sausages — the organism was present and functionally active for centuries or millennia, contributing to food preservation, flavor development, and reduction of pathogenic bacteria, long before its formal scientific description.

Both traditional and industrial foods have been supplemented with particular bacteria to improve taste, nutrition, and food safety. Fermentation is an important process to transform bioengineered food into safe, healthy, and green products. The intentional cultivation and deliberate commercial application of P. pentosaceus as an identified probiotic strain is, however, a product of late-twentieth and early-twenty-first century science.

4. Key Constituents, Active Compounds, and Mechanisms of Action

The bioactivity attributed to P. pentosaceus arises from a suite of metabolic products and structural cellular components. These include bacteriocins, exopolysaccharides (EPS), organic acids, short-chain fatty acids, gamma-aminobutyric acid (GABA), bile salt hydrolase (BSH), and various stress-response and immunomodulatory proteins encoded in the genome.

4.1 Bacteriocins and Bacteriocin-Like Inhibitory Substances (BLIS)

Bacteriocins are peptides produced by various species of bacteria, especially lactic acid bacteria, which have a large spectrum of action against spoilage bacteria and foodborne pathogens. Evidence suggests that bacteriocins or bacteriocin-like substances (BLISs) produced by P. pentosaceus play effective antibacterial roles in the microbial ecosystem.

Species of the genus Pediococcus are known to produce antimicrobial peptides such as pediocin-like bacteriocins that contain YGNGVXC as a conserved motif at their N-terminus. The molecular weight of various bacteriocins produced by different strains of the genus Pediococcus has been found to vary between 2.7 to 4.6 kDa. Among the known variants, pediocin PA-1 is a well-studied 4.6 kDa antimicrobial peptide with thermostability and wide pH range activity, though it is inactivated by proteases such as pepsin, trypsin, chymotrypsin, proteinase K, and pronase E. The structure of pediocin PA-1 reveals the presence of two β-strands connected by a β-hairpin made up of five amino acid residues in their N-terminal sequence, which play an important role in antimicrobial activity.

P. pentosaceus can produce bacteriocins active against several species of Lactobacillus, Lactococcus, Leuconostoc, Pediococcus, Staphylococcus, Enterococcus, Bacillus, and Listeria. These bacteriocins only inhibit Gram-positive microbes; Gram-negative bacteria were not inhibited in most classical pediocin preparations, though certain novel peptides from specific strains have demonstrated broader activity. In contrast to the typical narrow-spectrum activity shown by pediocin-like bacteriocins, certain novel antimicrobial peptides produced by specific P. pentosaceus strains have been found to inhibit the growth of both Gram-positive and Gram-negative indicator strains.

Pediocin-like bacteriocins are well-known to inhibit the growth of the food spoilage and pathogenic bacterium Listeria monocytogenes, and are therefore also termed anti-listerial bacteriocins and considered as potential antimicrobial additives for food preservation. Pediocin produced by Pediococcus pentosaceus is considered GRAS in certain food applications.

4.2 Exopolysaccharides (EPS)

Exopolysaccharides derived from lactic acid bacteria offer extraordinary health-promoting benefits, including immunomodulatory, anticancer, antioxidant, and antibacterial properties, while facilitating gut microbial colonization. Strains of P. pentosaceus are documented producers of diverse EPS structures. For example, the EPS from P. pentosaceus 4412 has been characterized as a neutral heteropolysaccharide, primarily composed of mannose with traces of glucose and rhamnose.

The anti-colitic mechanism of EPS from P. pentosaceus KFT18 has been studied in detail: PE-EPS reduced the enhanced expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) in colon tissue of colitis-induced mice. PE-EPS also protected against DSS-induced phosphorylation of p65 and signal transducer and activator of transcription 1 (STAT1). This indicates inhibition of the NF-κB and STAT1 pathways as key anti-inflammatory mechanisms.

4.3 Short-Chain Fatty Acid (SCFA) Production and Gut Microbiota Modulation

P. pentosaceus strains promote the production of short-chain fatty acids (SCFAs) both directly and by modulating intestinal microbiota composition. In colitis models, a significantly altered gut microbiota composition with increased diversity and SCFA production was observed in mice treated with P. pentosaceus LI05, and several genera, including Akkermansia and Faecalibacterium, were differentially enriched in treated mice, being negatively correlated with colitis indices and positively correlated with gut barrier markers and SCFA levels.

4.4 Bile Salt Hydrolase (BSH) and Cholesterol-Lowering Mechanism

Genes responsible for lowering cholesterol levels, including bile salt hydrolase (BSH), have been identified in the genomes of characterized P. pentosaceus strains. BSH catalyzes the deconjugation of bile salts, facilitating their excretion and thereby reducing the enterohepatic recycling of bile acids, which lowers serum cholesterol levels. In hyperlipidemia models, P. pentosaceus PP04 changed bile acid profiles and enhanced ileal concentrations of antagonists to inhibit intestinal farnesoid X receptor/fibroblast growth factor 15 (FXR/FGF15) signaling, coupled with the activation of hepatic FXR/small heterodimer partner signaling, which accelerated hepatic bile acid de novo synthesis and excretion with feces.

4.5 GABA Production

Certain P. pentosaceus strains have been documented as producers of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. The gene responsible for GABA synthesis, the glutamate/GABA antiporter (gadC), has been identified in the genomes of studied strains. GABA production by gut bacteria is considered relevant to the gut-brain axis, though direct clinical evidence specific to P. pentosaceus-derived GABA in humans remains preliminary.

4.6 Antioxidant Mechanisms

Research into P. pentosaceus in neurological contexts has revealed that it can affect the production of an oxidative stress response and the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) pathway-related proteins. The Nrf2 pathway is a master regulator of cellular antioxidant defense, and its activation by P. pentosaceus-derived signals represents a documented mechanistic pathway in animal studies.

4.7 Genomically Encoded Probiotic Traits

Functional genome annotations in studied strains have identified numerous genes associated with probiotic traits, including those involved in stress adaptation (e.g., heat stress: htpX, dnaK, and dnaJ), bile tolerance (e.g., ppaC), vitamin biosynthesis (e.g., ribU, ribZ, ribF, and btuD), immunomodulation (e.g., dltA, dltC, and dltD), and bacteriocin production (e.g., pedA).

5. Scientific Evidence by Area of Use

5.1 Gastrointestinal Health and Inflammatory Bowel Disease

Preclinical (animal) evidence: Several animal studies have examined P. pentosaceus in models of inflammatory bowel disease (IBD) and colitis.

In a mouse colitis model, mice were administered P. pentosaceus LI05 or phosphate-buffered saline once daily by oral gavage for 14 days, and colitis was induced by providing mice 2% DSS-containing drinking water for 7 days. P. pentosaceus LI05 ameliorated colitis in mice and reduced the body weight loss, disease activity index (DAI) scores, colon length shortening, intestinal permeability, and the proinflammatory cytokine levels. The treatment alleviated intestinal inflammation by maintaining the intestinal epithelial integrity and modulating the immunological profiles, gut microbiome, and metabolite composition.

In a separate study using EPS from P. pentosaceus KFT18, PE-EPS relieved DSS-induced colitis symptoms such as stool blood, decreased colon length, crypt disruption, and mucus layer edema in animal models.

Evidence strength: These findings are based exclusively on animal models (mice). No published randomized controlled trials in humans specifically evaluating P. pentosaceus for IBD or colitis have been identified in the available literature. Evidence is therefore rated as preliminary and preclinical only.

5.2 Obesity, Body Weight, and Metabolic Syndrome

Human clinical evidence (one RCT): The most notable human clinical trial involving P. pentosaceus was conducted with strain LP28 by researchers at Hiroshima University. The clinical trial was carried out as a double-blind, randomized, placebo-controlled study comprising 62 subjects (20–70 years of age, BMI 25–30 kg/m²). These subjects were randomly assigned to three groups that received living LP28, heat-killed LP28, or a placebo powder, administered orally once a day for 12 weeks. Heat-killed LP28 reduced BMI (0.45 kg/m², 95% CI 0.04–0.86, P=0.035), body fat percentage (1.11%, P=0.002), and body fat mass (1.17 kg, P=0.004). The intake of heat-killed LP28 for 12 weeks also reduced serum LDL cholesterol level and LDL/HDL ratio compared with the placebo.

The authors concluded that heat-killed LP28 displays an antiobesity effect that reduces BMI, body fat, and waist circumference, suggesting that the plant-derived lactic acid bacterium LP28 would be a promising preventive of metabolic syndrome.

Limitations: This trial was small (n=62), of short duration (12 weeks), used only one strain (LP28), and the investigators had a declared patent conflict of interest. Hiroshima University holds a patent on the use of LP28 as an antiobesity reagent, and principal investigators are co-inventors on that patent. The finding that heat-killed (not live) LP28 was the form that produced significant effects differentiates this from many probiotic mechanisms and requires further independent replication.

Evidence strength: Limited — a single small RCT with conflict of interest. Replication in independent, larger studies is needed.

5.3 Liver Health and Alcoholic Liver Disease

Preclinical evidence: P. pentosaceus CGMCC 7049 has been shown in animal studies to be resistant to ethanol and bile salts. In a murine model of alcoholic liver disease, application of a studied P. pentosaceus strain reduced levels of endotoxins and inflammatory cytokines including tumor necrosis factor-α, macrophage inflammatory protein-1α, and monocyte chemoattractant protein-1, and was able to restore microbial gut balance after the negative effect of ethanol. It also increased the levels of tight junction protein ZO-1, mucin proteins (MUC-1, MUC-2, and MUC-4), and the antimicrobial peptide Reg3β. P. pentosaceus supplementation restored the Firmicutes-to-Bacteroidetes ratio to a value similar to that of the control group following alcohol feeding.

Evidence strength: Preliminary — animal models only. No human clinical trials found in the available literature.

5.4 Cholesterol and Lipid Metabolism

Preclinical and genomic evidence: P. pentosaceus is characterized by its probiotic abilities, including the reduction of cholesterol levels. Strain ENM104, for example, is known for its inhibitory effects against pathogenic bacteria and its remarkable probiotic potential, including the induction of significant reductions in cholesterol levels. Previous studies have provided evidence demonstrating the effectiveness of P. pentosaceus in regulating disorders associated with lipid metabolism. In human clinical trials, P. pentosaceus LP28 showed antiobesity significance by downregulating total cholesterol (TC), triglycerides (TG), and LDL-C contents.

Evidence strength: The cholesterol-lowering effect in humans is documented in the same single LP28 RCT described above under obesity. Independent mechanistic evidence from animal models supports plausibility but clinical evidence remains limited.

5.5 Gut Microbiota Modulation and Resistance to Enteric Pathogens

Preclinical evidence: Research in a zebrafish model found that 3- or 4-week administration of a P. pentosaceus strain (YC) increased resistance against Aeromonas hydrophila, while 1- or 2-week treatment did not. Longer treatment significantly increased the abundance of short-chain fatty acid (SCFA)-producing bacteria and elevated the gene expression of nlrp3. Oral administration of P. pentosaceus LI05 for 14 days enhanced the survival rate of C. difficile-infected mice by increasing the abundance of beneficial microbial taxa and restraining opportunistic pathogens in the gut.

Evidence strength: Preclinical only (animal and in vitro). No RCTs in human subjects identified for enteric pathogen resistance.

5.6 Immune Modulation

Preclinical evidence: In a mouse model of influenza infection, oral administration of P. pentosaceus MIANGUAN2 significantly improved weight loss, lung index, and lung pathology, and decreased lung viral load. Additionally, treated mice showed significantly lower levels of pro-inflammatory cytokines TNF-α, IL-1β, IFN-γ, and IL-12p70, and higher production of IL-4 in the lung. Transcriptome analysis indicated that treated mice had reduced expression of inflammation markers, including TNF, apoptosis, and the NF-κB pathway.

Health-promoting effects have been associated with macrophage and immune system stimulation, anti-inflammation, anti-cancer, treatment of infant colic, and fatty liver disease in preclinical studies.

Evidence strength: Preclinical (animal models). No controlled human trials on immune outcomes identified.

5.7 Neurological and Gut-Brain Axis Research

Preclinical evidence: The antioxidant effect and mechanism of P. pentosaceus on Parkinson's disease (PD) was studied by regulating the gut-brain axis. In this study, male C57BL/6J mice were injected with MPTP intraperitoneally to establish a PD model and were treated with P. pentosaceus for 4 weeks. Treatment improved the MPTP-induced oxidative stress and was associated with changes in dopaminergic neuron degeneration, α-synuclein accumulation, and Nrf2 pathway protein expression. This body of work is exclusively in animal models.

Evidence strength: Very preliminary — animal model only. No human neurological trials identified.

5.8 Chemotherapy-Associated Intestinal Injury

Preclinical evidence: P. pentosaceus has a range of probiotic properties including antioxidant, immune, and cholesterol-lowering effects. Studies on the protective effect of P. pentosaceus against chemotherapy-induced intestinal mucositis caused by 5-fluorouracil (5-FU) have been conducted in animal models.

Evidence strength: Preclinical only.

5.9 Antimicrobial Activity in Food Systems

Pediococcus pentosaceus LBM 18 has been studied as a producer of an antibacterial and antifungal bacteriocin-like inhibitory substance (BLIS). The BLIS inhibited the growth of spoilage bacteria belonging to Lactobacillus, Enterococcus, and Listeria genera with higher activity than commercially available nisaplin used as control. It gave rise to inhibition halos with diameters from 9.70 to 20.00 mm. It also effectively suppressed the growth of fungi isolated from corn grain silage for up to 25 days and impaired morphology of colonies by likely affecting fungal membranes. These results indicate that P. pentosaceus BLIS may be a promising alternative to conventional antibacterial and antifungal substances, with potential applications in agriculture and the food industry as a natural bio-controlling agent.

Separately, in vitro assays using cell-free supernatants of P. pentosaceus ENM104 revealed antibacterial activity against carbapenem-resistant bacteria, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii, with inhibition zones increasing progressively over time.

6. Body Systems and Health Areas Associated with Pediococcus pentosaceus

• Gastrointestinal system: P. pentosaceus as a normal flora in gut microbiota plays a role in antioxidation, cholesterol-lowering, immune regulation, and cancer treatment.
• Hepatic system: Preclinical evidence for protection against alcoholic liver disease and restoration of gut-liver axis integrity.
• Cardiovascular/metabolic system: Cholesterol-lowering via bile salt hydrolase activity; documented reduction of LDL-C and triglycerides in one human RCT.
• Immune system: Modulation of innate and adaptive immune responses, including cytokine regulation and macrophage activation, documented in animal and in vitro studies.
• Central nervous system (gut-brain axis): GABA production and Nrf2 pathway modulation in preclinical models; entirely animal-level evidence.
• Respiratory system: Gut-lung axis evidence from animal influenza models.

7. Dosage Forms and Dosages Reported in Studies

P. pentosaceus is administered in various forms. The following dosages have been specifically reported in peer-reviewed sources:

• Human RCT (LP28, obesity): 62 subjects (BMI 25–30 kg/m²) were administered living LP28, heat-killed LP28, or placebo powder orally once a day for 12 weeks. The form that achieved statistical significance was the heat-killed preparation.
• Silage/feed additive: P. pentosaceus as a technological additive is intended for use at a minimum proposed dose of 1 × 10⁸ colony-forming units (CFU)/kg fresh material in ensiling applications.
• EFSA-assessed feed additive (NCIMB 12674): Proposed minimum concentration of 1 × 10⁹ CFU/kg fresh plant material.
• Preclinical colitis model (LI05): Mice were administered P. pentosaceus LI05 once daily by oral gavage for 14 days.
• Preclinical pathogen resistance model: 3- to 4-week administration of a P. pentosaceus strain was required to increase resistance against Aeromonas hydrophila; 1- or 2-week treatment did not achieve this effect.

No standardized human clinical dosing recommendations for P. pentosaceus as a dietary supplement have been established by any regulatory authority based on the sources reviewed.

8. Safety Considerations

8.1 Regulatory Status

P. pentosaceus holds GRAS status by the United States FDA, supporting its widespread use across the food fermentation industry. The species P. pentosaceus is considered by EFSA to be suitable for the Qualified Presumption of Safety (QPS) approach to safety assessment, and does not require specific demonstration of safety other than the absence of resistance to antibiotics of human and veterinary significance. For each strain of P. pentosaceus that claims QPS status, a scientific report is published by EFSA. In these reports, identification of the strain is verified along with the absence of antibiotic resistance, and other specific experiments of efficacy and allergenic effects from their use are also conducted.

8.2 Antibiotic Resistance

Antibiotic resistance is a central safety criterion assessed by EFSA for any P. pentosaceus strain intended for deliberate addition to the food or feed chain. One P. pentosaceus strain assessed by EFSA (NCIMB 30044) was found to be resistant to tetracycline by an unidentified mechanism, and thus may pose a risk for the spread of genes coding for resistance to an antibiotic of human and veterinary importance. Because of this, the additive containing this particular strain was not considered safe.

In contrast, where genomic screening identifies no acquired resistance genes, EFSA has concluded differently: the identity of strain NCIMB 12674 was established, and no acquired antimicrobial resistance genes were detected; therefore, the FEEDAP Panel concluded that the use of the strain as a silage additive is considered safe for all animal species, for consumers of products from animals fed with the treated silage, and for the environment. Although that strain was phenotypically resistant to tetracycline, since no acquired AMR genes were found in whole-genome sequencing, this resistance does not raise safety concerns.

In the fight against the spread of antibiotic resistance, authorities require that strains "intentionally added into the food chain" be tested for their antibiotic susceptibility. This applies to strains used in starter or adjunct cultures for the production of fermented foods, such as many strains of Pediococcus pentosaceus. The European Food Safety Authority recommends testing strains for their antibiotic susceptibility based on both genomic and phenotypic approaches.

It has been noted that Pediococcus spp. are intrinsically resistant to numerous groups of antibiotics encompassing β-lactams, cephalosporins, aminoglycosides, glycopeptides, streptomycin, kanamycin, tetracyclines, and sulfa compounds. Antibiotic resistance as such is not a safety concern, but it becomes a serious peril when resistance is transferable.

8.3 Occupational and Handling Safety

Regarding user safety in occupational handling, inhalation and dermal exposure is considered a risk. No conclusions can be drawn on the eye irritancy potential of certain preparations. This applies primarily to industrial-scale handling of concentrated freeze-dried preparations, not to typical consumer probiotic use.

8.4 Virulence and Pathogenicity

No known diseases are caused by Pediococcus pentosaceus under normal circumstances. Whole-genome sequence data from characterized strains, when searched for known toxins and virulence factors using VirulenceFinder, identified no hits.

However, there are documented rare cases of opportunistic infection in the broader Pediococcus genus. When applied to the human body, P. pentosaceus can also be harmful to health if it is not in the correct location. Research has found that P. pentosaceus produced abrupt inflammation in clinical use, resembling Saccharopolyspora rectivirgula. These events are rare and documented predominantly in severely immunocompromised patients.

8.5 Strain Specificity and the Absence of Universal Conclusions

A critical safety and efficacy consideration is that P. pentosaceus is not a single organism but a diverse species comprising many strains with different properties. Selecting the most promising strain of P. pentosaceus is an important task, as is the preparation of complete bacterial formulations and systematic and complete evaluation of the characteristics and disadvantages of specific strains. Safety conclusions drawn for one strain cannot be automatically applied to another, and EFSA assesses each strain individually.

9. Current Research Status and Limitations

Current studies on P. pentosaceus are not yet complete in their characterization. The organism plays a role in antioxidation, cholesterol-lowering, immune regulation, and cancer treatment as a normal flora component in gut microbiota. Its notable cholesterol-lowering, GABA-producing, and antimicrobial capabilities suggest promising applications in the pharmaceutical and food industries. Future research should focus on further exploring these functional properties and assessing the strain's efficacy in clinical settings.

The overall evidence base for P. pentosaceus as a human dietary supplement or clinical probiotic agent is largely preclinical. With the exception of one small, industry-linked RCT for heat-killed LP28 on obesity-related parameters, there are no large-scale, independently replicated, placebo-controlled human trials for any of the health claims attributed to this organism. Most mechanistic and efficacy data derive from in vitro cell culture studies and rodent or zebrafish animal models, which may not directly translate to human health outcomes. The species demonstrates substantial strain-to-strain genomic and functional variability, meaning that findings from one strain cannot be generalized to the species as a whole.

References

• Pediococcus pentosaceus PP34 Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis via Inhibiting Oxidative Stress and Restoring the Gut Microbiota — PubMed
• Assessment of the in-vitro probiotic efficacy and safety of Pediococcus pentosaceus L1 and Streptococcus thermophilus L3 isolated from Laban — PubMed
• Probiotic Pediococcus pentosaceus ameliorates MPTP-induced oxidative stress via regulating the gut microbiota-gut-brain axis — PubMed
• Pediococcus pentosaceus MIANGUAN2 Alleviates Influenza Virus Infection by Modulating Gut Microbiota and Enhancing Short-Chain Fatty Acid Production — PMC
• Genomic Insights into Pediococcus pentosaceus ENM104: A Probiotic with Potential Antimicrobial and Cholesterol-Reducing Properties — PMC
• Potential Probiotic Pediococcus pentosaceus M41 Modulates Its Proteome Differentially for Tolerances Against Heat, Cold, Acid, and Bile Stresses — PMC
• Pediococcus pentosaceus, a future additive or probiotic candidate — Microbial Cell Factories / PMC
• Whole-genome analysis suggesting probiotic potential and safety properties of Pediococcus pentosaceus DSPZPP1 — Frontiers in Microbiology
• Pediococcus pentosaceus: Screening and Application as Probiotics in Food Processing — Frontiers in Microbiology
• Pediococcus pentosaceus, a future additive or probiotic candidate — Microbial Cell Factories, Springer Nature
• Comparative Genomics of Pediococcus pentosaceus Isolated From Different Niches Reveals Genetic Diversity in Carbohydrate Metabolism and Immune System — PMC
• A non-pediocin low molecular weight antimicrobial peptide produced by Pediococcus pentosaceus strain IE-3 — PMC
• Antibacterial and antifungal activity of crude and freeze-dried bacteriocin-like inhibitory substance produced by Pediococcus pentosaceus — PMC / Scientific Reports
• Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial — PubMed (European Journal of Clinical Nutrition, 2016)
• Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects — European Journal of Clinical Nutrition, Nature
• NCT01685944: Anti-Obesity Effect of Pediococcus Pentosaceus LP28 — ClinicalTrials.gov
• The Obesity and Fatty Liver Are Reduced by Plant-Derived Pediococcus pentosaceus LP28 in High Fat Diet-Induced Obese Mice — PLOS ONE
• Pediococcus pentosaceus CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice — PMC
• Pediococcus pentosaceus LI05 alleviates DSS-induced colitis by modulating immunological profiles, the gut microbiota and short-chain fatty acid levels in a mouse model — PMC
• Anti-Colitic Effect of an Exopolysaccharide Fraction from Pediococcus pentosaceus KFT-18 on Dextran Sulfate Sodium-Induced Colitis — PMC
• New strain of Pediococcus pentosaceus alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism — PMC
• Pediococcus pentosaceus Enhances Host Resistance Against Pathogen by Increasing IL-1β Production — PMC
• Pediococcus pentosaceus (NCIMB 30044) for all species — EFSA Journal
• Safety and efficacy of Pediococcus pentosaceus DSM 32291 as a silage additive for all animal species — EFSA Journal
• Safety and efficacy of a feed additive consisting of Pediococcus pentosaceus NCIMB 12674 for all animal species — EFSA / PMC
• Safety and efficacy of a feed additive consisting of Pediococcus pentosaceus IMI 507024 for all animal species — EFSA / PMC
• Complete Genome Sequence of Pediococcus pentosaceus Strain wikim 20, Isolated from Korean Kimchi — PMC
• Complete Genome Sequence of Pediococcus pentosaceus Strain SL4 — PMC
• Beneficial features of pediococcus: from starter cultures and inhibitory activities to probiotic benefits — PMC
• Probiotic Properties of Pediococcus pentosaceus JBCC 106 and Its Lactic Acid Fermentation on Broccoli Juice — PMC
• Mechanism of Pediococcus pentosaceus PP04 in alleviating high-fat diet caused hyperlipidemia via modulation of intestinal flora and metabolites — Food Science and Human Wellness
• Pediococcus pentosaceus PR-1 modulates high-fat-diet-induced alterations in gut microbiota, inflammation, and lipid metabolism in zebrafish — Frontiers in Nutrition
• Assessing the Probiotic Effects of Pediococcus pentosaceus CACC616 in Weaned Piglets — PMC
• Pediococcus pentosaceus — MicrobeWiki, Kenyon College
• Pediococcus pentosaceus — ScienceDirect Topics Overview
• Comparative Analyses of Pediococcus pentosaceus Strains Isolated from Milk Cattle Reveal New Insights for Screening Food-Protective Cultures — PMC